K
Kim A. Eagle
Researcher at University of Michigan
Publications - 852
Citations - 85694
Kim A. Eagle is an academic researcher from University of Michigan. The author has contributed to research in topics: Aortic dissection & Myocardial infarction. The author has an hindex of 129, co-authored 823 publications receiving 75160 citations. Previous affiliations of Kim A. Eagle include University of Wisconsin Hospital and Clinics & Spaulding Rehabilitation Hospital.
Papers
More filters
Journal ArticleDOI
Is size a good predictor of dissection risk in patients with marfan syndrome or bicuspid aortic valves? insights from the international registry of acute aortic dissection (irad)
Hasan K. Siddiqi,Eric M. Isselbacher,Toru Suzuki,Daniel G. Montgomery,Linda Pape,Rossella Fattori,Patrick T. O'Gara,Guillaume Jondeau,Emil Missov,Alberto Forteza,Eduardo Bossone,Alan T. Hirsch,Adam M. Rogers,Christoph A. Nienaber,Kim A. Eagle +14 more
Journal ArticleDOI
Has the ClOpidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early β-blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE).
Jeremy Edwards,Shaun G. Goodman,Raymond T. Yan,Robert C. Welsh,Jan M. Kornder,J. Paul DeYoung,Denis Chauret,Jean-Pierre Picard,Kim A. Eagle,Andrew T. Yan +9 more
TL;DR: There has been no significant change in the use of BB in patients with STEMI or NSTEACS after controlling for their clinical characteristics since the publication of COMMIT/CCS-2, and long-term BB use, higher systolic blood pressure, and higher heart rate were independent predictors of early BB use.
Journal ArticleDOI
Usefulness of low-density lipoprotein particle size measurement in cardiovascular disease prevention
TL;DR: The measurement of low‐density lipoprotein particle size (LDLPS) is a novel cardiovascular risk factor, yet it is unknown whether this measurement provides additional information that may influence the subsequent medical treatment of patients.
Journal ArticleDOI
Effects of Cerivastatin Withdrawal on Statin Persistence
Kristen T Reaume,Steven R. Erickson,Michael P. Dorsch,Niquole L M Dunham,Susan M. Hiniker,Nitya Prabhakar,Eva Kline-Rogers,Kim A. Eagle +7 more
TL;DR: The temporary decline in statin persistence appeared to be associated with the withdrawal of cerivastatin, while persistence with the other study medications remained constant.
Journal ArticleDOI
Quality improvement in acute coronary syndromes: translating evidence into practice.
TL;DR: The evidence for the importance of guideline adherence in the management of ACS is examined, predictors of adherence to these guidelines are explored, and evidence-based strategies for improving their implementation are provided.